Cardiff Oncology Stock Operating Margin
| CRDF Stock | USD 2.43 0.01 0.41% |
Fundamental analysis of Cardiff Oncology allows traders to better anticipate movements in Cardiff Oncology's stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Cardiff Oncology Company Operating Margin Analysis
Cardiff Oncology's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Cardiff Oncology Operating Margin | (122.12) % |
Most of Cardiff Oncology's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardiff Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Cardiff Oncology has an Operating Margin of -122.124%. This is 248.13% higher than that of the Biotechnology sector and 8.97% higher than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Did you try this?
Run Price Exposure Probability Now
Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets |
| All Next | Launch Module |
Cardiff Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (122.12) % | ||||
| Current Valuation | 92.55 M | ||||
| Shares Outstanding | 66.53 M | ||||
| Shares Owned By Insiders | 6.05 % | ||||
| Shares Owned By Institutions | 39.91 % | ||||
| Number Of Shares Shorted | 18.84 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 2.77 X | ||||
| Price To Sales | 297.84 X | ||||
| Revenue | 683 K | ||||
| Gross Profit | (40.86 M) | ||||
| EBITDA | (48.25 M) | ||||
| Net Income | (45.43 M) | ||||
| Cash And Equivalents | 122.01 M | ||||
| Cash Per Share | 2.82 X | ||||
| Total Debt | 1.52 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.02 X | ||||
| Book Value Per Share | 0.88 X | ||||
| Cash Flow From Operations | (37.69 M) | ||||
| Short Ratio | 7.01 X | ||||
| Earnings Per Share | (0.87) X | ||||
| Target Price | 10.07 | ||||
| Number Of Employees | 32 | ||||
| Beta | 1.54 | ||||
| Market Capitalization | 162.32 M | ||||
| Total Asset | 97.19 M | ||||
| Retained Earnings | (384.18 M) | ||||
| Working Capital | 81.63 M | ||||
| Current Asset | 16.9 M | ||||
| Current Liabilities | 4.78 M | ||||
| Net Asset | 97.19 M |
About Cardiff Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| HLN | Haleon plc | |
| NVDA | NVIDIA | |
| INTC | Intel | |
| GFS | Globalfoundries | |
| SMCI | Super Micro Computer |
Check out Cardiff Oncology Piotroski F Score and Cardiff Oncology Altman Z Score analysis. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.